

Bruce A Chabner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5413786/publications.pdf>

Version: 2024-02-01

102
papers

3,905
citations

257450
24
h-index

123424
61
g-index

105
all docs

105
docs citations

105
times ranked

7569
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). Cancer Research, 2022, 82, P2-07-02-P2-07-02.	0.9	1
2	Joseph R. Bertino, Scientist and Clinical Oncologist. Journal of Clinical Oncology, 2022, , JCO2102693.	1.6	0
3	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature Medicine, 2022, 28, 620-626.	30.7	13
4	Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants. JCO Oncology Practice, 2022, 18, e1427-e1437.	2.9	4
5	A Medical Pearl Harbor: Pandemic Uncovers Societal Fissures and Leadership Breaches. Oncologist, 2021, 26, 89-89.	3.7	0
6	An Homage to Two Explorers of Uncharted Cancer Waters. Oncologist, 2021, 26, 350-351.	3.7	0
7	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research and Treatment, 2021, 189, 641-651.	2.5	16
8	The Occasional Reader. Oncologist, 2021, 26, e1484-e1485.	3.7	0
9	Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. JCO Global Oncology, 2021, 7, 1620-1632.	1.8	0
10	Remembering Joe. Oncologist, 2021, 26, 1085-1086.	3.7	0
11	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	3.0	16
12	The Corruption of Science. Oncologist, 2020, 25, 907-908.	3.7	3
13	The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. JCO Global Oncology, 2020, 6, 13-13.	1.8	1
14	Racism and Cancer Care: A Call for Recognition and Reform. Oncologist, 2020, 25, 729-729.	3.7	3
15	A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist, 2020, 25, 652-660.	3.7	11
16	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist, 2020, 25, 747-e1273.	3.7	9
17	The Finding of N-Nitrosodimethylamine in Common Medicines. Oncologist, 2020, 25, 460-462.	3.7	15
18	Taking the Longer View of COVID â€”19. Oncologist, 2020, 25, 455-457.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Twenty-Five Years of The Oncologist. Oncologist, 2020, 25, 1-2.	3.7	21
20	Cell-free DNA Analysis in Cancer. New England Journal of Medicine, 2019, 380, 501-502.	27.0	12
21	Immuno-Oncology in China. Oncologist, 2019, 24, S1-S2.	3.7	0
22	The Other Opioid Crisis: Just Another Drug Shortage?. Oncologist, 2019, 24, 574-575.	3.7	5
23	POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. Oncologist, 2019, 24, 1557-1561.	3.7	12
24	Canakinumab and Lung Cancer: Intriguing, but Is It Real?. Oncologist, 2018, 23, 637-638.	3.7	15
25	Does Chemotherapy Induce Metastases?. Oncologist, 2018, 23, 273-274.	3.7	9
26	Considerations About the Use of Biomarkers in Cancer Clinical Trials. Clinical Pharmacology and Therapeutics, 2018, 103, 25-27.	4.7	2
27	Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana. Journal of Global Oncology, 2018, 4, 1-11.	0.5	14
28	Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research. Oncologist, 2018, 23, 1391-1393.	3.7	3
29	Application of Cell-free DNA Analysis to Cancer Treatment. New England Journal of Medicine, 2018, 379, 1754-1765.	27.0	634
30	Design and clinical validation of a point-of-care device for the diagnosis of lymphoma via contrast-enhanced microholography and machine learning. Nature Biomedical Engineering, 2018, 2, 666-674.	22.5	55
31	Let This Be Our New Year's Pledge. Oncologist, 2017, 22, 1-2.	3.7	42
32	Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies". Oncologist, 2017, 22, 757-758.	3.7	2
33	Advantages of a Truly Open-Access Data-Sharing Model. New England Journal of Medicine, 2017, 376, 1178-1181.	27.0	79
34	The Harm in Kratom. Oncologist, 2017, 22, 1010-1011.	3.7	10
35	On Losing Paddy Johnston. Oncologist, 2017, 22, 1014-1014.	3.7	0
36	Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted Oncology, 2017, 12, 719-739.	3.6	71

#	ARTICLE	IF	CITATIONS
37	Thoughts About Greg Curt. Oncologist, 2016, 21, 1277-1277.	3.7	1
38	Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications. Theranostics, 2016, 6, 1603-1610.	10.0	12
39	Reflections on 2015. Oncologist, 2016, 21, 129-130.	3.7	0
40	Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. Oncologist, 2016, 21, 467-474.	3.7	70
41	While We're at It, Let's Whack the FDA. Oncologist, 2016, 21, 259-260.	3.7	2
42	Understanding the Precision in "Precision Medicine". Oncologist, 2016, 21, 1029-1030.	3.7	0
43	HIV Infection and Survival Among Women With Cervical Cancer. Journal of Clinical Oncology, 2016, 34, 3749-3757.	1.6	129
44	NCI-60 Cell Line Screening: A Radical Departure in its Time. Journal of the National Cancer Institute, 2016, 108, djv388.	6.3	71
45	Recognizing the Financial Burden of Cancer Patients in Clinical Trials. Oncologist, 2015, 20, 572-575.	3.7	43
46	Breakthrough Drugs and Turtle Soup. Oncologist, 2015, 20, 845-846.	3.7	1
47	Structural Approaches to Cancer Drug Development. New England Journal of Medicine, 2015, 373, 402-403.	27.0	2
48	Two Decades of The Oncologist. Oncologist, 2015, 20, 1-2.	3.7	25
49	Ponatinib: Accelerated Disapproval. Oncologist, 2015, 20, 847-848.	3.7	51
50	Improving Prospects for Targeting RAS. Journal of Clinical Oncology, 2015, 33, 3650-3659.	1.6	89
51	Defining a New Role for the National Cancer Institute Cooperative Groups: More Science, Fewer Trials. Oncologist, 2014, 19, 1113-1114.	3.7	1
52	Effective double whammy targets DNA synthesis in leukemia. Journal of Experimental Medicine, 2014, 211, 384-385.	8.5	0
53	The Untimely Passing of a Great Man: Eddie Reed, M.D., 1953-2014. Oncologist, 2014, 19, 786-787.	3.7	1
54	Pharmacodynamic Biomarkers: Falling Short of the Mark?. Clinical Cancer Research, 2014, 20, 2587-2594.	7.0	41

#	ARTICLE	IF	CITATIONS
55	Approval After Phase I: Ceritinib Runs the Three-Minute Mile. <i>Oncologist</i> , 2014, 19, 577-578.	3.7	31
56	Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 468-475.	0.8	34
57	Resolution: Refresh, Recharge, Renew. <i>Oncologist</i> , 2013, 18, 1-1.	3.7	3
58	Approval of New Agents after Phase II Trials. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , e1-e3.	3.8	3
59	Early Accelerated Approval for Highly Targeted Cancer Drugs. <i>New England Journal of Medicine</i> , 2011, 364, 1087-1089.	27.0	74
60	Drug Shortages – A Critical Challenge for the Generic-Drug Market. <i>New England Journal of Medicine</i> , 2011, 365, 2147-2149.	27.0	90
61	About Eli. <i>Oncologist</i> , 2010, 15, 329-331.	3.7	0
62	Obituary. <i>Cancer Science</i> , 2009, 100, 565-566.	3.9	0
63	Advances and challenges in the use of biomarkers in clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 42-3.	0.3	2
64	Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.. <i>Blood</i> , 2007, 110, 256-256.	1.4	0
65	Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.. <i>Blood</i> , 2006, 108, 3454-3454.	1.4	0
66	Chemotherapy and the war on cancer. <i>Nature Reviews Cancer</i> , 2005, 5, 65-72.	28.4	1,646
67	Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 159-159.	1.4	4
68	Cancer therapy and survivorship. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 269s.	2.5	0
69	A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 16-22.	3.7	2
70	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. <i>Oncologist</i> , 2002, 7, 58-65.	3.7	7
71	Cytotoxic Agents in the Era of Molecular Targets and Genomics. <i>Oncologist</i> , 2002, 7, 34-41.	3.7	86
72	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 50-57.	3.7	1

#	ARTICLE	IF	CITATIONS
73	A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 8-15.	3.7	4
74	A Staff Dialogue on Caring for a Cancer Patient Who Commits Suicide: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 30-35.	3.7	22
75	About Sorrow. Oncologist, 2002, 7, 5-6.	3.7	0
76	A Staff Dialogue on Aggressive Palliative Treatment Demanded by a Terminally Ill Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 23-29.	3.7	4
77	A Staff Dialogue on Do Not Resuscitate Orders: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 36-42.	3.7	5
78	When Does the Responsibility of Our Care End: Bereavement. Oncologist, 2002, 7, 251-258.	3.7	36
79	Cytotoxic Agents in the Era of Molecular Targets and Genomics. Oncologist, 2002, 7, 34-41.	3.7	5
80	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. Oncologist, 2002, 7, 58-65.	3.7	0
81	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 50-57.	3.7	0
82	A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 8-15.	3.7	0
83	A Staff Dialogue on Aggressive Palliative Treatment Demanded by a Terminally Ill Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 23-29.	3.7	0
84	About Sorrow. Oncologist, 2002, 7, 5-6.	3.7	0
85	A Staff Dialogue on Caring for a Cancer Patient Who Commits Suicide: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 30-35.	3.7	4
86	Losing God. Oncologist, 2001, 6, 286-297.	3.7	12
87	Complementary, Alternative, Integrative, or Unconventional Medicine?. Oncologist, 2001, 6, 463-473.	3.7	24
88	Medical Mistakes: A Workshop on Personal Perspectives. Oncologist, 2001, 6, 92-99.	3.7	45
89	Caring for Colleagues. Oncologist, 2001, 6, 197-204.	3.7	4
90	New Drugs for Cancer: Temozolomide. Oncologist, 2000, 5, 0-1.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Communicating Genetic Risk: Pros, Cons, and Counsel. <i>Oncologist</i> , 2000, 5, 152-161.	3.7	5
92	Sexuality and Cancer: Conversation Comfort Zone. <i>Oncologist</i> , 2000, 5, 336-344.	3.7	52
93	A Staff Dialogue on Caring for a Cancer Patient Who Commits Suicide: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 122-127.	3.7	1
94	A Staff Dialogue on Aggressive Palliative Treatment Demanded by a Terminally Ill Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 70-76.	3.7	3
95	A Staff Dialogue on Do Not Resuscitate Orders: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 256-262.	3.7	7
96	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 417-424.	3.7	1
97	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. <i>Oncologist</i> , 1999, 4, 501-508.	3.7	17
98	Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, S3-S21.	2.3	25
99	A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1998, 3, 439-445.	3.7	3
100	A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1998, 3, 357-364.	3.7	3
101	Back to the Future for Clinical Oncology. <i>Oncologist</i> , 1996, 1, i-i.	3.7	2
102	Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders. <i>Oncologist</i> , 1996, 1, 125-139.	3.7	14